{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T16:36:21Z","timestamp":1777307781191,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005378","name":"Hacettepe University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005378","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Chronic inflammation in inborn errors of immunity(IEI) caused by the infections or immune dysregulation is associated with the amyloid A (AA) amyloidosis development. This study aims to analyze the clinical characteristics, management strategies, and outcomes of patients with IEI complicated by AA amyloidosis, focusing on demographics, disease manifestations, treatment modalities, and survival rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Thirteen patients diagnosed with IEI and AA amyloidosis, along with an additional 10 patients previously reported from T\u00fcrkiye, were reviewed retrospectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The median ages at diagnosis of IEI and amyloidosis were 20 years (2\u201361) and 25 years (7\u201370), respectively. Renal (74%) and gastrointestinal involvement (44%) were the most common, followed by skin(9%), pulmonary (9%), and cardiac involvement (9%). Primary antibody deficiencies(48%), combined immunodeficiencies(31%), hyperimmunoglobulin E syndrome(9%), congenital neutropenia (4%), autoinflammatory disorders (4%), and chronic mucocutaneous candidiasis (4%) were the IEI types associated with amyloidosis. Bronchiectasis (74%) and malignancy (17%) were observed in given ratio of patients. Treatment modalities for amyloidosis include colchicine (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200912, 52%), steroids (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095, 22%) and tocilizumab (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092, 9%) without significant benefit. Thirteen patients (57%) died with a median age of 24 years (8\u201345), predominantly due to sepsis (52%). Familial Mediterranean fever (FMF) gene analysis was negative in all patients except for one, who had a heterozygous MEFV gene defect (M694V).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>AA amyloidosis in IEI is associated with severe morbidity and mortality. Early diagnosis and management of IEI are crucial to prevent amyloidosis development. However, colchicine appears ineffective once amyloidosis has occurred, highlighting the need for further research into early diagnostic biomarkers and novel treatment options.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10875-025-01875-1","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T02:20:34Z","timestamp":1745374834000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Amyloidosis in Human Inborn Errors of Immunity Predicts Poor Prognosis"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2329-7543","authenticated-orcid":false,"given":"Elif Soyak","family":"Aytekin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anar","family":"Tagiyev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onat","family":"Silleli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130ncinur","family":"Samur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fevzi","family":"Demirel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saliha","family":"Esenbo\u011fa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emine Arzu","family":"Sa\u011flam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2213-4627","authenticated-orcid":false,"given":"Deniz","family":"\u00c7a\u011fda\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"issue":"23","key":"1875_CR1","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1056\/NEJMoa070265","volume":"356","author":"HJ Lachmann","year":"2007","unstructured":"Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356(23):2361\u201371.","journal-title":"N Engl J Med"},{"key":"1875_CR2","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s10545-015-9842-8","volume":"38","author":"L Millucci","year":"2015","unstructured":"Millucci L, Braconi D, Bernardini G, Lupetti P, Rovensky J, Ranganath L, et al. Amyloidosis in alkaptonuria. J Inherit Metab Dis. 2015;38:797\u2013805.","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"1875_CR3","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.jaip.2020.09.023","volume":"9","author":"M Delplanque","year":"2021","unstructured":"Delplanque M, Galicier L, Oziol E, Ducharme-B\u00e9nard S, Oksenhendler E, Buob D, et al. AA amyloidosis secondary to primary immune deficiency: about 40 cases including 2 new French cases and a systematic literature review. J Allergy Clin Immunology: Pract. 2021;9(2):745\u201352. e1.","journal-title":"J Allergy Clin Immunology: Pract"},{"issue":"1","key":"1875_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms6360","volume":"5","author":"KL Willmann","year":"2014","unstructured":"Willmann KL, Klaver S, Do\u011fu F, Santos-Valente E, Garncarz W, Bilic I, et al. Biallelic loss-of-function mutation in NIK causes a primary immunodeficiency with multifaceted aberrant lymphoid immunity. Nat Commun. 2014;5(1):1\u201313.","journal-title":"Nat Commun"},{"issue":"4","key":"1875_CR5","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S0002-9149(97)89403-9","volume":"77","author":"SW Dubrey","year":"1996","unstructured":"Dubrey SW, Cha K, Simms RW, Skinner M, Falk RH. Electrocardiography and doppler echocardiography in secondary (AA) amyloidosis. Am J Cardiol. 1996;77(4):313\u20135.","journal-title":"Am J Cardiol"},{"key":"1875_CR6","doi-asserted-by":"crossref","unstructured":"Basset M, Sch\u00f6nland SO, Obici L, G\u00fcnther J, Riva E, Dittrich T et al. Development and validation of staging systems for AA amyloidosis. J Am Soc Nephrol. 2024:101681.","DOI":"10.1681\/ASN.0000000000000339"},{"issue":"5","key":"1875_CR7","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jaci.2016.12.978","volume":"140","author":"A Fischer","year":"2017","unstructured":"Fischer A, Provot J, Jais J-P, Alcais A, Mahlaoui N, Adoue D, et al. Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies. J Allergy Clin Immunol. 2017;140(5):1388\u201393. e8.","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"1875_CR8","first-page":"2445","volume":"25","author":"S Ozen","year":"1998","unstructured":"Ozen S, Karaaslan Y, Ozdemir O, Saatci U, Bakkaloglu A, Koroglu E, et al. Prevalence of juvenile chronic arthritis and Familial mediterranean fever in Turkey: a field study. J Rhuematol. 1998;25(12):2445\u20139.","journal-title":"J Rhuematol"},{"issue":"4","key":"1875_CR9","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1093\/rheumatology\/ket400","volume":"53","author":"T Kasifoglu","year":"2014","unstructured":"Kasifoglu T, Bilge SY, Sari I, Solmaz D, Senel S, Emmungil H, et al. Amyloidosis and its related factors in Turkish patients with Familial mediterranean fever: a multicentre study. Rheumatology. 2014;53(4):741\u20135.","journal-title":"Rheumatology"},{"issue":"1","key":"1875_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/13506129.2014.980942","volume":"22","author":"N Blank","year":"2015","unstructured":"Blank N, Hegenbart U, Lohse P, Beimler J, R\u00f6cken C, Ho AD, et al. Risk factors for AA amyloidosis in Germany. Amyloid. 2015;22(1):1\u20137.","journal-title":"Amyloid"},{"issue":"2","key":"1875_CR11","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.autrev.2005.10.002","volume":"5","author":"AK Knight","year":"2006","unstructured":"Knight AK, Cunningham-Rundles C. Inflammatory and autoimmune complications of common variable immune deficiency. Autoimmun Rev. 2006;5(2):156\u20139.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"1875_CR12","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.jaip.2018.12.017","volume":"7","author":"JW Leiding","year":"2019","unstructured":"Leiding JW, Forbes LR. Mechanism-based precision therapy for the treatment of primary immunodeficiency and primary immunodysregulatory diseases. J Allergy Clin Immunology: Pract. 2019;7(3):761\u201373.","journal-title":"J Allergy Clin Immunology: Pract"},{"key":"1875_CR13","doi-asserted-by":"crossref","unstructured":"Gennery AR. Hematopoietic stem cell transplantation for primary immune deficiencies. Stiehm\u2019s Immune Deficiencies. 2020:1175\u2013214.","DOI":"10.1016\/B978-0-12-816768-7.00057-0"},{"issue":"16","key":"1875_CR14","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJM198604173141601","volume":"314","author":"D Zemer","year":"1986","unstructured":"Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J. Colchicine in the prevention and treatment of the amyloidosis of Familial mediterranean fever. N Engl J Med. 1986;314(16):1001\u20135.","journal-title":"N Engl J Med"},{"issue":"5","key":"1875_CR15","doi-asserted-by":"publisher","first-page":"426","DOI":"10.7326\/0003-4819-116-5-426_1","volume":"116","author":"D Zemer","year":"1992","unstructured":"Zemer D, Livneh A, Langevitz P. Reversal of the nephrotic syndrome by Colchicine in amyloidosis of Familial mediterranean fever. Ann Intern Med. 1992;116(5):426.","journal-title":"Ann Intern Med"},{"issue":"10","key":"1875_CR16","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1093\/ecco-jcc\/jjw080","volume":"10","author":"J Tosca Cuquerella","year":"2016","unstructured":"Tosca Cuquerella J, Bosca-Watts MM, Anton Ausejo R, Tejedor Alonso S, Mora De Miguel F, Minguez Perez M. Amyloidosis in inflammatory bowel disease: a systematic review of epidemiology, clinical features, and treatment. J Crohn\u2019s Colitis. 2016;10(10):1245\u201353.","journal-title":"J Crohn\u2019s Colitis"},{"key":"1875_CR17","doi-asserted-by":"publisher","first-page":"102713","DOI":"10.1016\/j.jaut.2021.102713","volume":"124","author":"M Hemed-Shaked","year":"2021","unstructured":"Hemed-Shaked M, Cowman MK, Kim JR, Huang X, Chau E, Ovadia H, et al. MTADV 5-MER peptide suppresses chronic inflammations as well as autoimmune pathologies and unveils a new potential target-serum amyloid A. J Autoimmun. 2021;124:102713.","journal-title":"J Autoimmun"},{"key":"1875_CR18","doi-asserted-by":"crossref","unstructured":"Lachmann HJ. Periodic fever syndromes. Best practice & research Clinical rheumatology. 2017;31(4):596\u2013609.","DOI":"10.1016\/j.berh.2017.12.001"},{"key":"1875_CR19","doi-asserted-by":"crossref","unstructured":"Jung J-Y, Kim Y-B, Kim J-w, Suh C-H, Kim H-A. Biologic therapy for amyloid A amyloidosis secondary to rheumatoid arthritis treated with Interleukin 6 therapy: case report and review of literature. Medicine. 2021;100(32).","DOI":"10.1097\/MD.0000000000026843"},{"issue":"1","key":"1875_CR20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.autrev.2012.07.016","volume":"12","author":"L Obici","year":"2012","unstructured":"Obici L, Merlini G. Amyloidosis in autoinflammatory syndromes. Autoimmun Rev. 2012;12(1):14\u20137.","journal-title":"Autoimmun Rev"},{"key":"1875_CR21","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ejim.2020.08.012","volume":"82","author":"A Terr\u00e9","year":"2020","unstructured":"Terr\u00e9 A, Deshayes S, Savey L, Grateau G, Georgin-Lavialle S. Cause of death and risk factors for mortality in AA amyloidosis: a French retrospective study. Eur J Intern Med. 2020;82:130\u20132.","journal-title":"Eur J Intern Med"},{"issue":"6375","key":"1875_CR22","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1136\/bmj.286.6375.1391","volume":"286","author":"HM Falck","year":"1983","unstructured":"Falck HM, Maury C, Teppo A-M, Wegelius O. Correlation of persistently high serum amyloid A protein and C-reactive protein concentrations with rapid progression of secondary amyloidosis. Br Med J (Clin Res Ed). 1983;286(6375):1391\u20133.","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"6","key":"1875_CR23","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3349\/ymj.2005.46.6.847","volume":"46","author":"AF \u00c7el\u0131k","year":"2005","unstructured":"\u00c7el\u0131k AF, Altiparmak MR, Pamuk GE, Pamuk \u00d6N, Tabak F. Association of secondary amyloidosis with common variable immune deficiency and tuberculosis. Yonsei Med J. 2005;46(6):847.","journal-title":"Yonsei Med J"},{"issue":"5","key":"1875_CR24","first-page":"456","volume":"3","author":"Z Aydin","year":"2010","unstructured":"Aydin Z, Gursu M, Ozturk S, Kilicaslan I, Kazancioglu R. A case of primary immune deficiency presenting with nephrotic syndrome. NDT Plus. 2010;3(5):456\u20138.","journal-title":"NDT Plus"},{"issue":"2","key":"1875_CR25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.clim.2014.07.003","volume":"154","author":"S Borte","year":"2014","unstructured":"Borte S, Celiksoy MH, Menzel V, Ozkaya O, Ozen FZ, Hammarstr\u00f6m L, et al. Novel NLRP12 mutations associated with intestinal amyloidosis in a patient diagnosed with common variable immunodeficiency. Clin Immunol. 2014;154(2):105\u201311.","journal-title":"Clin Immunol"},{"key":"1875_CR26","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s10875-015-0151-7","volume":"35","author":"S Arslan","year":"2015","unstructured":"Arslan S, Ucar R, Yavsan DM, Esen H, Maden E, Reisli I, et al. Common variable immunodeficiency and pulmonary amyloidosis: a case report. J Clin Immunol. 2015;35:344\u20137.","journal-title":"J Clin Immunol"},{"key":"1875_CR27","doi-asserted-by":"crossref","unstructured":"Kadiro\u011flu AK, Y\u0131ld\u0131r\u0131m Y, Y\u0131lmaz Z, Kayaba\u015f\u0131 H, Avc\u0131 Y, Y\u0131ld\u0131r\u0131m MS et al. A rare cause of secondary amyloidosis: common variable immunodeficiency disease. Case Reports in Nephrology. 2012;2012.","DOI":"10.1155\/2012\/860208"},{"issue":"5","key":"1875_CR28","doi-asserted-by":"publisher","first-page":"401","DOI":"10.4103\/0256-4947.67085","volume":"30","author":"K Turkmen","year":"2010","unstructured":"Turkmen K, Anil M, Solak Y, Atalay H, Esen H, Tonbul HZ. A hepatitis C-positive patient with new onset of nephrotic syndrome and systemic amyloidosis secondary to common variable immunodeficiency. Ann Saudi Med. 2010;30(5):401\u20133.","journal-title":"Ann Saudi Med"},{"issue":"9","key":"1875_CR29","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1093\/ndt\/15.9.1480","volume":"15","author":"A \u00d6ner","year":"2000","unstructured":"\u00d6ner A, Demircin G, Erdo\u011fan \u00d6, B\u00fclb\u00fcl M, Memi\u015f L, Arda N, et al. A family with hyperimmunoglobulin M syndrome and systemic amyloidosis. Nephrol Dialysis Transplantation. 2000;15(9):1480\u20132.","journal-title":"Nephrol Dialysis Transplantation"},{"issue":"3","key":"1875_CR30","first-page":"467","volume":"39","author":"D Soysal","year":"2009","unstructured":"Soysal D, T\u00fcrkkan E, Karaku\u015f V, Tatar E, KABAYE\u011e\u0130T \u00d6Y, Avci A. A case of common variable immunodeficiency disease and thyroid amyloidosis. Turk J Med Sci. 2009;39(3):467\u201373.","journal-title":"Turk J Med Sci"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-025-01875-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-025-01875-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-025-01875-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T15:45:35Z","timestamp":1777304735000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-025-01875-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1875"],"URL":"https:\/\/doi.org\/10.1007\/s10875-025-01875-1","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]},"assertion":[{"value":"2 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"All authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Due to retrospective nature of the study, informed consent was not required by the ethical committee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}}],"article-number":"88"}}